دورية أكاديمية
أعرض في EDS

Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia.

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of chloroquine plus primaquine for the treatment of Plasmodium vivax malaria in Hamusit site, Northwestern Ethiopia.
المؤلفون: Gebrie H; Department of Medical Laboratory Science College of Medicine and Health Science, Dilla University, Dilla, Ethiopia. habtamugebrie2012@gmail.com., Yimer M; Department of Medical Laboratory Science College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia., Ayehu A; Department of Medical Laboratory Science College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia., Mohammed H; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Hailgiorgis H; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Wuletaw Y; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Hailu M; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Tolera G; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Tasew G; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Kassa M; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Gidey B; Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
المصدر: Malaria journal [Malar J] 2024 Jul 06; Vol. 23 (1), pp. 202. Date of Electronic Publication: 2024 Jul 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Malaria, Vivax*/drug therapy , Chloroquine*/therapeutic use , Chloroquine*/administration & dosage , Chloroquine*/adverse effects , Primaquine*/therapeutic use , Primaquine*/administration & dosage , Antimalarials*/therapeutic use , Antimalarials*/administration & dosage , Antimalarials*/adverse effects , Drug Therapy, Combination* , Plasmodium vivax*/drug effects, Ethiopia ; Humans ; Adolescent ; Male ; Adult ; Young Adult ; Female ; Child ; Prospective Studies ; Middle Aged ; Child, Preschool ; Aged
مستخلص: Background: Plasmodium vivax malaria is still an important public health problem in Ethiopia. Unlike Plasmodium falciparum, P. vivax has a dormant liver stage (hypnozoite) that can be a risk of recurrent vivax malaria unless treated by radical cure with primaquine. Drug resistance to chloroquine is threatening malaria control and elimination efforts. This study assessed the therapeutic efficacy and safety of chloroquine plus 14 days of primaquine on P. vivax infection based on parasitological, clinical, and haematological parameters.
Methods: A single-arm in vivo prospective therapeutic efficacy study was conducted to assess the clinical and parasitological response to the first-line treatment of P. vivax in Ethiopia, chloroquine plus 14 days low dose of (0.25 mg/kg/day) primaquine between December 2022 and March 2023 at Hamusit Health Centre using the standard World Health Organization (WHO) protocol. A total of 100 study participants with P. vivax mono-infection who were over 6 months old were enrolled and monitored for adequate clinical and parasitological responses for 42 days. The WHO double-entry Excel sheet and SPSS v.25 software were used for Kaplan-Meier survival analysis, and a paired t-test was used for analysis of haemoglobin improvements between follow up days.
Results: A total of 100 patients were enrolled among those, 96% cases were rural residents, 93% had previous malaria exposure, and predominant age group was 5-15 years (61%). 92.6% (95% CI 85.1-96.4%) of enrolled patients were adequate clinical and parasitological response, and 7.4% (95% CI 3.6-14.9%) recurrences were observed among treated patients. The fever and parasite clearance rate on day 3 were 98% and 94%, respectively. The baseline haemoglobin levels improved significantly compared to those days 14 and 42 (p < 0.001). No serious adverse event was observed during the study period.
Conclusions: In this study, co-administration of chloroquine with primaquine was efficacious and well-tolerated with fast resolution of fever and high parasites clearance rate. However, the 7.4% failure is reported is alarming that warrant further monitoring of the therapeutic efficacy study of P. vivax.
(© 2024. The Author(s).)
References: Parasit Vectors. 2011 Mar 31;4:46. (PMID: 21453465)
Pathog Glob Health. 2016;110(1):1-8. (PMID: 27077309)
Clin Diagn Lab Immunol. 2001 Nov;8(6):1164-70. (PMID: 11687458)
Am J Trop Med Hyg. 1964 Jan;13:SUPPL 237-9. (PMID: 14104823)
Trends Parasitol. 2002 May;18(5):224-30. (PMID: 11983604)
Malar J. 2017 Feb 23;16(1):88. (PMID: 28231817)
Am J Trop Med Hyg. 2007 Feb;76(2):203-7. (PMID: 17297026)
Malar J. 2015 Dec 24;14:525. (PMID: 26702611)
Lancet Infect Dis. 2018 Sep;18(9):1025-1034. (PMID: 30033231)
Trends Parasitol. 2009 May;25(5):220-7. (PMID: 19349210)
Malar J. 2015 Aug 11;14:310. (PMID: 26259839)
Infection. 2022 Jun;50(3):681-688. (PMID: 35034327)
Acta Trop. 2010 Feb;113(2):105-13. (PMID: 19835832)
Clin Pharmacokinet. 1996 Oct;31(4):257-74. (PMID: 8896943)
Ann Acad Med Singap. 2016 Jul;45(7):303-14. (PMID: 27523511)
Elife. 2018 Jul 25;7:. (PMID: 30044224)
Am J Trop Med Hyg. 2019 Jan;100(1):72-77. (PMID: 30457097)
PLoS One. 2023 Jan 12;18(1):e0277362. (PMID: 36634046)
Antimicrob Agents Chemother. 2013 Mar;57(3):1246-51. (PMID: 23262997)
Malar J. 2023 Apr 25;22(1):135. (PMID: 37098510)
Acta Trop. 2017 Jul;171:44-51. (PMID: 28300558)
J Infect Dis. 2004 Sep 15;190(6):1183-91. (PMID: 15319870)
Travel Med Infect Dis. 2020 Jul - Aug;36:101499. (PMID: 31604130)
Clin Microbiol Rev. 2009 Jul;22(3):508-34. (PMID: 19597012)
Lancet Infect Dis. 2014 Oct;14(10):982-91. (PMID: 25213732)
Antimicrob Agents Chemother. 2019 Apr 25;63(5):. (PMID: 30782991)
Antimicrob Agents Chemother. 2015 Feb;59(2):1230-5. (PMID: 25512415)
Am J Trop Med Hyg. 2003 Apr;68(4):410-2. (PMID: 12875288)
فهرسة مساهمة: Keywords: Plasmodium vivax; Chloroquine; Drug efficacy; Ethiopia; Primaquine
المشرفين على المادة: 886U3H6UFF (Chloroquine)
MVR3634GX1 (Primaquine)
0 (Antimalarials)
تواريخ الأحداث: Date Created: 20240706 Date Completed: 20240706 Latest Revision: 20240709
رمز التحديث: 20240709
مُعرف محوري في PubMed: PMC11227712
DOI: 10.1186/s12936-024-05031-9
PMID: 38971786
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2875
DOI:10.1186/s12936-024-05031-9